Emergent BioSolutions Announces Appointment of Marvin White to the Company’s Board of Directors
August 26 2020 - 6:30AM
Emergent BioSolutions Inc. (NYSE:EBS) announced today that the
company’s board of directors appointed Marvin L. White as a Class
II director to serve on the board effective October 1, 2020, with
an initial term expiring at the 2023 annual meeting of
stockholders. Mr. White was also appointed as a member of both the
Scientific Review Committee and Strategic Operations Committee of
the board.
“We welcome Marvin back to Emergent’s Board of Directors,” said
Fuad El-Hibri, executive chairman of the board of Emergent
BioSolutions. “He brings invaluable financial and management
expertise gained from his time in the pharmaceutical and healthcare
sectors. We look forward to his contributions in advising company
leadership on how to further grow and increase shareholder
value.”
“I am delighted to serve on the board of a mission-driven
organization focused on public health,” said Mr. White. “As
Emergent executes on its growth strategy, I embrace the opportunity
to work with my distinguished colleagues on the board as well as
the management team to help move the company forward.”
Mr. White has served as president and chief executive officer
and member of the board of directors of Aptevo Therapeutics Inc.
since August 2016. He previously served on Emergent’s board from
2010 to 2016. Prior to that, he served as chief financial officer
of St. Vincent Health and was responsible for finance, patient
financial services, and managed care for 19 hospitals and 36 joint
ventures. Previously, he was chief financial officer of Lilly USA,
a subsidiary of Eli Lilly and Company, where he also held
leadership positions in Corporate Finance and Investment
Banking.
Prior to his career in healthcare, Mr. White held leadership
positions at General Motors, Hewlett-Packard, and Motorola,
including financial roles for its Japan, South Asia and Latin
America Cellular Group. He currently serves on the board of
OneAmerica Financial Insurance Partners, Inc. Mr. White earned his
Bachelor of Science degree in Accounting from Wilberforce
University and his Master of Business Administration in Finance
from Indiana University.
About Emergent BioSolutionsEmergent
BioSolutions is a global life sciences company whose mission is to
protect and enhance life. Through our specialty products and
contract development and manufacturing services, we are dedicated
to providing solutions that address public health threats. Through
social responsibility, we aim to build healthier and safer
communities. We aspire to deliver peace of mind to our patients and
customers so they can focus on what’s most important in their
lives. In working together, we envision protecting or enhancing 1
billion lives by 2030. For more information visit
www.emergentbiosolutions.com. Find us on LinkedIn and follow us on
Twitter @emergentbiosolu and Instagram @life_at_emergent.
Safe Harbor StatementThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any statements,
other than statements of historical fact, including, but no limited
to, statements regarding executing on our growth strategy and
increasing shareholder value, are forward-looking statements. These
forward-looking statements are based on our current intentions,
beliefs and expectations regarding future events. We cannot
guarantee that any forward-looking statement will be accurate.
Investors should realize that if underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual
results could differ materially from our expectations. Investors
are, therefore, cautioned not to place undue reliance on any
forward-looking statement. Any forward-looking statement speaks
only as of the date of this press release, and, except as required
by law, we do not undertake to update any forward-looking statement
to reflect new information, events or circumstances. There are a
number of important factors that could cause our actual results to
differ materially from those indicated by such forward-looking
statements. Investors should consider this cautionary statement as
well as the risk factors identified in our periodic reports filed
with the Securities and Exchange Commission when evaluating our
forward-looking statements.
Investor Contact:Robert G. BurrowsVice
President, Investor Relations240-631-3280
burrowsr@ebsi.com
Media Contact:Miko B. NeriSenior Director,
Global Communications & Public Affairs240-631-3392
nerim@ebsi.com
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Apr 2023 to Apr 2024